Evidence map›Paper›PMID 25609251›Full record

ArticleThe Journal of biological chemistry2015

Tyrosyl-DNA phosphodiesterase I catalytic mutants reveal an alternative nucleophile that can catalyze substrate cleavage.

Evan Q Comeaux, Selma M Cuya, Kyoko Kojima, Nauzanene Jafari, Keith C Wanzeck, James A Mobley, Mary-Ann Bjornsti, Robert C A M van Waardenburg

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Zymolyase Treatment ofDNA and cell biology · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Evan Q ComeauxFrom the Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama 35294.
Selma M CuyaFrom the Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama 35294.
Kyoko Kojimathe University of Alabama at Birmingham Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama 35294.
Nauzanene JafariDepartment of Molecular Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, and.
Keith C WanzeckFrom the Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama 35294.
James A Mobleythe Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama 35294.
Mary-Ann BjornstiFrom the Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama 35294.
Robert C A M van WaardenburgFrom the Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama 35294, rvanwaar@uab.edu.
University of Alabama at Birmingham · US

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9M
DNA TOPOISOMERASE-CAMPTOTHECIN INTERACTIONSR01CA058755 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BJORNSTI, MARY-ANN · 1993 to 2011
$3.2M
NCI NIH HHS 5P30CA013148NCI NIH HHS CA58755NCI NIH HHS P30 CA013148NCI NIH HHS R01 CA058755
6 · The paper itself

Abstract

Tyrosyl-DNA phosphodiesterase I (Tdp1) catalyzes the repair of 3'-DNA adducts, such as the 3'-phosphotyrosyl linkage of DNA topoisomerase I to DNA. Tdp1 contains two conserved catalytic histidines: a nucleophilic His (His(nuc)) that attacks DNA adducts to form a covalent 3'-phosphohistidyl intermediate and a general acid/base His (His(gab)), which resolves the Tdp1-DNA linkage. A His(nuc) to Ala mutant protein is reportedly inactive, whereas the autosomal recessive neurodegenerative disease SCAN1 has been attributed to the enhanced stability of the Tdp1-DNA intermediate induced by mutation of His(gab) to Arg. However, here we report that expression of the yeast His(nuc)Ala (H182A) mutant actually induced topoisomerase I-dependent cytotoxicity and further enhanced the cytotoxicity of Tdp1 His(gab) mutants, including H432N and the SCAN1-related H432R. Moreover, the His(nuc)Ala mutant was catalytically active in vitro, albeit at levels 85-fold less than that observed with wild type Tdp1. In contrast, the His(nuc)Phe mutant was catalytically inactive and suppressed His(gab) mutant-induced toxicity. These data suggest that the activity of another nucleophile when His(nuc) is replaced with residues containing a small side chain (Ala, Asn, and Gln), but not with a bulky side chain. Indeed, genetic, biochemical, and mass spectrometry analyses show that a highly conserved His, immediately N-terminal to His(nuc), can act as a nucleophile to catalyze the formation of a covalent Tdp1-DNA intermediate. These findings suggest that the flexibility of Tdp1 active site residues may impair the resolution of mutant Tdp1 covalent phosphohistidyl intermediates and provide the rationale for developing chemotherapeutics that stabilize the covalent Tdp1-DNA intermediate.

Indexed as

CatalysisCatalytic DomainCrystallography, X-RayDNADNA AdductsDNA DamageDNA RepairDNA Topoisomerases, Type IHumansMultiprotein ComplexesMutant ProteinsPhosphoric Diester HydrolasesSpinocerebellar AtaxiasDNADNA AdductsDNA Topoisomerases, Type IMultiprotein ComplexesMutant ProteinsPhosphoric Diester HydrolasesTDP1 protein, humanTOP1 protein, humanDNA DamageDNA RepairDNA TopoisomeraseEnzyme MechanismEnzyme MutationProtein-DNA Covalent ComplexesSpinocerebellar Ataxia with Axonal Neuropathy 1Tyrosyl-DNA Phosphodiesterase I

Identifiers

PMID25609251
PMCPMC4358259
OpenAlexW1996432141

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.